MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Omeros Corp

Closed

SectorHealthcare

7.23 3.58

Overview

Share price change

24h

Current

Min

6.76

Max

7.29

Key metrics

By Trading Economics

Income

874K

-31M

EPS

-0.541

Employees

202

EBITDA

-239K

-33M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+270.01% upside

Dividends

By Dow Jones

Next Earnings

14 May 2025

Market Stats

By TradingEconomics

Market Cap

-102M

389M

Previous open

3.65

Previous close

7.23

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Omeros Corp Chart

Past performance is not a reliable indicator of future results.

Related News

24 Apr 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Alphabet, Intel, AppFolio

24 Apr 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 Apr 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 Apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 Apr 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 Apr 2025, 23:36 UTC

Top News

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 Apr 2025, 23:13 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 Apr 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 Apr 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 Apr 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 Apr 2025, 22:51 UTC

Top News
Acquisitions, Mergers, Takeovers

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 Apr 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 Apr 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 Apr 2025, 22:38 UTC

Market Talk
Earnings

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 Apr 2025, 22:24 UTC

Earnings

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 Apr 2025, 22:24 UTC

Earnings

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 Apr 2025, 22:24 UTC

Market Talk
Earnings

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 Apr 2025, 22:23 UTC

Earnings

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 Apr 2025, 22:11 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

24 Apr 2025, 22:11 UTC

Market Talk
Earnings

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 Apr 2025, 22:09 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 Apr 2025, 22:00 UTC

Market Talk
Earnings

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 Apr 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 Apr 2025, 21:24 UTC

Top News
Earnings

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 Apr 2025, 21:24 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 Apr 2025, 21:23 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 Apr 2025, 21:04 UTC

Earnings

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 Apr 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 Apr 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 Apr 2025, 21:02 UTC

Earnings

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer Comparison

Price change

Omeros Corp Forecast

Price Target

By TipRanks

270.01% upside

12 Months Forecast

Average 25.79 USD  270.01%

High 45 USD

Low 6.583 USD

Based on 3 Wall Street analysts offering 12 month price targets forOmeros Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

6.7901 / 6.99Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.